RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 21, 2017, Dr. Richard Mangano, Relmada Therapeutics, Inc.’s (the “Company”) Chief Scientific Officer, resigned from the Company to return to academia. Dr. Mangano’s departure is not related to any issues regarding the Company’s operations, policies or practices. Dr. Mangano will continue to work with the Company as a consultant.
About RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD)
Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies. RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Recent Trading Information
RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) closed its last trading session down -0.06 at 1.04 with shares trading hands.